Literature DB >> 15690232

Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia.

B T Yilmaz1, B Alioglu, E Ozyurek, H T Akay, S Mercan, N Ozbek.   

Abstract

Glanzmann thrombasthenia is a rare, hereditary, congenital disorder of platelet function characterized by inappropriate bleeding that is difficult to control. Recombinant activated factor VII (rFVIIa) is a new treatment that is used to stop bleeding and provide surgical support for these patients. This report describes the use of rFVIIa to prevent serious bleeding during and after open-heart surgery in a child with Glanzmann thrombasthenia.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15690232     DOI： 10.1007/s00246-004-0919-7

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN： 0172-0643            Impact factor:   1.655


  11 in total

1.  Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures.

Authors:  R d'Oiron; C Ménart; M C Trzeciak; P Nurden; E Fressinaud; M Dreyfus; Y Laurian; C Négrier
Journal:  Thromb Haemost       Date:  2000-05       Impact factor: 5.249

2.  Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding.

Authors:  M P Smith; C A Ludlam; P W Collins; C R Hay; J T Wilde; A Grigeri; T Melsen; G F Savidge
Journal:  Thromb Haemost       Date:  2001-10       Impact factor: 5.249

Review 3.  Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000.

Authors:  U Hedner
Journal:  Semin Thromb Hemost       Date:  2000       Impact factor: 4.180

4.  A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa.

Authors:  L Tengborn; B Petruson
Journal:  Thromb Haemost       Date:  1996-06       Impact factor: 5.249

Review 5.  Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group.

Authors:  S Schulman
Journal:  Haemophilia       Date:  1998-07       Impact factor: 4.287

6.  Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery.

Authors:  M Al Douri; T Shafi; D Al Khudairi; E Al Bokhari; L Black; N Akinwale; M Osman Musa; A Al Homaidhi; M Al Fagih; R Borum Andreasen
Journal:  Blood Coagul Fibrinolysis       Date:  2000-04       Impact factor: 1.276

7.  Use of recombinant factor VIIa for post-operative haemorrhage in a patient with Glanzmann's thrombasthenia and human leucocyte antigen antibodies.

Authors:  R K Patel; G F Savidge; S Rangarajan
Journal:  Br J Haematol       Date:  2001-07       Impact factor: 6.998

8.  Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.

Authors:  E Santagostino; M Morfini; A Rocino; F Baudo; F A Scaraggi; A Gringeri
Journal:  Thromb Haemost       Date:  2001-10       Impact factor: 5.249

9.  Heart transplant in a factor VIII-deficient patient with a high-titre inhibitor: perioperative management using high-dose continuous infusion factor VIII and recombinant factor VIIa.

Authors:  S Sheth; D Dimichele; M Lee; J Lamour; J Quaegebeur; D Hsu; L Addonizio; S Piomelli
Journal:  Haemophilia       Date:  2001-03       Impact factor: 4.287

10.  Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.

Authors:  A D Shapiro; G S Gilchrist; W K Hoots; H A Cooper; D A Gastineau
Journal:  Thromb Haemost       Date:  1998-11       Impact factor: 5.249
View more
  4 in total

1.  Recombinant activated factor VII and epsilon aminocaproic acid treatment of a patient with Glanzmann's thrombasthenia for nasal polipectomy.

Authors:  Berrin Gunaydin; Zerrin Ozkose; Seyda Pezek
Journal:  J Anesth       Date:  2007-01-30       Impact factor: 2.078

2.  Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with congenital factor XI deficiency.

Authors:  Zekai Avci; Baris Malbora; Mahmut Gokdemir; Suleyman Ozkan; Namik Ozbek
Journal:  Pediatr Cardiol       Date:  2007-09-20       Impact factor: 1.655

Review 3.  Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.

Authors:  Man-Chiu Poon
Journal:  Vasc Health Risk Manag       Date:  2007

4.  Perioperative management of a patient with glanzmann's thrombasthenia for mitral valve repair under cardiopulmonary bypass.

Authors:  Parimala Prasanna Simha; Prasanna Simha Mohan Rao; Deepak Arakalgud; Rakesh Rajashekharappa; Manjunath Narasimhaih
Journal:  Ann Card Anaesth       Date:  2017 Oct-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.